SAN FRANCISCO, CA--(Marketwired - Nov 25, 2014) - Medivation, Inc. (NASDAQ: MDVN) today announced that Joseph Lobacki will join the company as chief commercial officer on December 8, 2014. In this position, Mr. Lobacki will lead commercial development strategy including the marketing and sales functions, reporting to David Hung, M.D., president and chief executive officer of Medivation. He will succeed Dawn Svoronos, who has served as Medivation's interim chief commercial officer since July 2014.

"On behalf of the board and the executive committee, we are very excited to welcome Joe to our team," said David Hung, M.D., president and chief executive officer of Medivation. "Joe's extensive global commercialization expertise in oncology sales and marketing make him a key addition to the team as we continue to grow our existing business and look to instill a strong commercial perspective in our future development efforts."

Mr. Lobacki added, "I am privileged to join such a successful organization and contribute to the continued growth of XTANDI and future products. It is exciting to be part of the opportunity at Medivation to bring medically-innovative therapies to patients with serious diseases."

Mr. Lobacki brings almost 30 years of experience in marketing, operations, sales and medical affairs at major pharmaceutical companies. Previously, Mr. Lobacki served as the general manager of the oncology business at Idera Pharmaceuticals, senior vice president and chief commercial officer at Micromet Inc., senior vice president and general manager of transplant and oncology at Genzyme Corporation, vice president of North American marketing at SangStat Medical Corporation and vice president of operations at Cell Pathways, Inc. Mr. Lobacki currently serves on the Board of Directors for Celator Pharmaceuticals. Mr. Lobacki holds a Bachelor of Science degree in Biology from Boston College and a Bachelor of Science degree in Pharmacy from Massachusetts College of Pharmacy.

About Medivation
 Medivation, Inc. is a biopharmaceutical company focused on the rapid development of medically-innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, visit www.medivation.com